Silexion reports breakthrough in KRAS cancer therapy
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
Yahoo Finance3d
Silexion Therapeutics Corp (SLXN)
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
Silexion Therapeutics (SLXN) Gets a Buy from Maxim Group
In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...
Nasdaq7d
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Cayman Islands, January 29, 2025-- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...